Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Kalinsky

Showing results (11-20 of 151) with videos related to

Pageof 16
Sort By:
Current Treatment Options in Oncology|June 14, 2023
CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?Elizabeth Sakach, Merve Keskinkilic, Sarah Wood, et al.
Clinical Sarcoma Research|November 18, 2014
Concomitant angiosarcoma and lymphoproliferative disorder in solid organ transplant recipientsLea N Baer, David G Savage, Hanina H Hibshoosh, et al.
Breast Cancer Research and Treatment|May 28, 2011
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progressionKevin Kalinsky, Adriana Heguy, Umeshkumar K Bhanot, et al.
Expert Review of Anticancer Therapy|September 29, 2023
The role of immune checkpoint inhibition in triple negative breast cancerKidist Tarekegn, Merve Keskinkilic, Tyler J Kristoff, et al.
Nature Reviews. Clinical Oncology|August 23, 2024
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancerMaxwell R Lloyd, Komal Jhaveri, Kevin Kalinsky, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 28, 2026
Navigating Treatment Decisions in Early-Stage Hormone Receptor-Positive Breast CancerEitan Amir, Tyler Kristoff, Catherine Blaha, et al.
Elife|December 29, 2025
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancerJessica Armand, Sungsoo Kim, Kibum Kim, et al.
Clinical Breast Cancer|July 20, 2017
Invasive Lobular Breast Carcinoma: Pleomorphic Versus Classical Subtype, Associations and PrognosisYing L Liu, Christine Choi, Shing M Lee, et al.
Breast Cancer Research and Treatment|May 27, 2016
Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapyYing L Liu, Anurag Saraf, Shing M Lee, et al.
Clinical Medicine Insights. Oncology|September 24, 2016
Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case StudyNikita Consul, Xiaotao Guo, Courtney Coker, et al.
Pageof 16

Showing results (11-20 of 151) with videos related to

Sort By:
Pageof 16
Current Treatment Options in Oncology|June 14, 2023
CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?Elizabeth Sakach, Merve Keskinkilic, Sarah Wood, et al.
Clinical Sarcoma Research|November 18, 2014
Concomitant angiosarcoma and lymphoproliferative disorder in solid organ transplant recipientsLea N Baer, David G Savage, Hanina H Hibshoosh, et al.
Breast Cancer Research and Treatment|May 28, 2011
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progressionKevin Kalinsky, Adriana Heguy, Umeshkumar K Bhanot, et al.
Expert Review of Anticancer Therapy|September 29, 2023
The role of immune checkpoint inhibition in triple negative breast cancerKidist Tarekegn, Merve Keskinkilic, Tyler J Kristoff, et al.
Nature Reviews. Clinical Oncology|August 23, 2024
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancerMaxwell R Lloyd, Komal Jhaveri, Kevin Kalinsky, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 28, 2026
Navigating Treatment Decisions in Early-Stage Hormone Receptor-Positive Breast CancerEitan Amir, Tyler Kristoff, Catherine Blaha, et al.
Elife|December 29, 2025
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancerJessica Armand, Sungsoo Kim, Kibum Kim, et al.
Clinical Breast Cancer|July 20, 2017
Invasive Lobular Breast Carcinoma: Pleomorphic Versus Classical Subtype, Associations and PrognosisYing L Liu, Christine Choi, Shing M Lee, et al.
Breast Cancer Research and Treatment|May 27, 2016
Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapyYing L Liu, Anurag Saraf, Shing M Lee, et al.
Clinical Medicine Insights. Oncology|September 24, 2016
Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case StudyNikita Consul, Xiaotao Guo, Courtney Coker, et al.
Pageof 16